ART Provider and Patient Resource to Improve Communication about Outcomes and Treatment (APRICOT)

项目摘要/摘要 据估计，8%-12%的育龄夫妇会受到不孕不育的影响，导致许多人寻求帮助 生殖技术(ART)治疗，如体外受精(IVF)、配子输卵管内移植 (GIFT)和受精卵输卵管内移植(ZIFT)。在美国出生的婴儿中，约有1.9% 年份是用艺术构思的。1992年生育临床成功率和认证法案(FCSRCA) 要求每年进行抗逆转录病毒治疗的诊所向疾病中心报告成功率数据 控制和预防(CDC)；然而，诊所在收集准确的妊娠结局方面面临挑战 来自这些患者或患者新的医疗保健提供者的信息。为了收集怀孕结果，ART 诊所依靠传统的外展方式，包括电话、邮件和电子邮件，从 病人，他们可能不在州甚至国家，以及他们的产科提供者。这一过程需要大量的 努力，通常需要多次尝试。然而，收集这些信息很重要，因为疾控中心使用 ART监测数据，以监测在美国进行的治疗的成功率，并表征 ART对患者和ART治疗后受孕婴儿的短期和长期健康影响。 为了提高响应率和数据质量，同时降低每位患者的成本，Charles River Analytics和 我们的合作者，马萨诸塞州总医院的Shruthi Mahalingaiah博士建议设计和评估 ART提供者和患者资源，以改善关于结果和治疗的沟通(APRICOT)。 Aricot是一种健康信息技术(HIT)应用程序，用于减轻辅助生殖的负担 技术(ART)诊所与收集现有技术患者的妊娠结局和 患者的其他医疗保健提供者。在这一阶段的努力下，我们将使用人因工程学方法， 包括定性研究方法、情景设计和用户接受度测试，以引出临床和患者 用户需求，设计候选工作流和用户界面，并论证开发的可行性 杏子。我们的努力将建立艺术诊所和患者用户需求，并为 妊娠结局报告平台，促进ART诊所和 他们的病人。杏子将使生育诊所能够有效地收集妊娠结局信息并 有效地从现有技术的患者和患者的其他保健提供者那里获得。杏子将帮助诊所 通过减少诊所工作人员收集数据所需的工作量来满足联邦规定的报告要求 来自以前的抗逆转录病毒治疗患者和他们的产科提供者的妊娠结局信息，帮助临床 在收集以前患者的妊娠结局时实现时间和金钱成本的节省。

Project Summary/Abstract Infertility affects an estimated 8-12% of reproductive-aged couples, leading many to seek assisted reproductive technologies (ART) treatments such as in vitro fertilization (IVF), gamete intrafallopian transfer (GIFT), and zygote intrafallopian transfer (ZIFT). Approximately 1.9% of infants born in the United States each year are conceived using ART. The Fertility Clinic Success Rate and Certification Act (FCSRCA) of 1992 mandates that clinics performing ART treatment annually report success rate data to the Centers for Disease Control and Prevention (CDC); however, clinics face challenges in collecting accurate pregnancy outcome information from these patients or the patients' new healthcare providers. To collect pregnancy outcomes, ART clinics rely on traditional outreach methods, including telephone, mail, and email, to obtain information from patients, who may be out of state or even country, and their obstetric providers. This process requires significant effort, often requiring multiple attempts. However, collecting this information is important because the CDC uses ART surveillance data to monitor the success rates of treatments performed in the U.S. and to characterize the short- and long-term health effects of ART on patients and infants conceived after ART treatments. To improve the response rates and data quality while reducing per patient costs, Charles River Analytics and our collaborator, Dr. Shruthi Mahalingaiah from Massachusetts General Hospital, propose to design and evaluate an ART Provider and Patient Resource to Improve Communication about Outcomes and Treatment (APRICOT). APRICOT is a health information technology (HIT) application to alleviate the burden on assisted reproductive technology (ART) clinics associated with collecting pregnancy outcomes from prior ART patients and the patients' other healthcare providers. Under this Phase I effort, we will use human factors engineering methods, including qualitative research methods, contextual design, and user acceptance testing, to elicit clinic and patient user requirements, design candidate workflows and user interfaces, and demonstrate the feasibility of developing APRICOT. Our effort will establish ART clinic and patient user requirements and produce conceptual designs for a pregnancy outcome reporting platform that facilitates streamlined communication between ART clinics and their patients. APRICOT will enable fertility clinics to collect pregnancy outcome information efficiently and effectively from prior ART patients and the patients' other healthcare providers. APRICOT will assist clinics in meeting federally mandated reporting requirements by reducing the effort required of clinic staff to collect pregnancy outcome information from previous ART patients and their obstetric providers, helping clinics to realize time and monetary cost savings in collecting pregnancy outcomes from prior patients.